Aplicações clínicas de imunoglobulina em
                        doenças neuromusculares com foco em miopatias
                        inflamatórias

Souza, Paulo Victor Sgobbi de; Pinto, Wladimir Bocca Vieira de Rezende; Oliveira, Acary Souza Bulle

doi:10.1590/0004-282X20140160

Acessibilidade / Reportar erro

Brasil

Arquivos de Neuro-Psiquiatria

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

View and Review • Arq. Neuro-Psiquiatr. 72 (12) • Dez 2014 • https://doi.org/10.1590/0004-282X20140160 copiar

Aplicações clínicas de imunoglobulina em doenças neuromusculares com foco em miopatias inflamatórias

Autoria SCIMAGO INSTITUTIONS RANKINGS

Nos últimos anos, um número progressivo de doenças neuromusculares passaram a ser reconhecidas tanto por ser causadas por mecanismos autoimunes ou por envolver importantes componentes autoimunes. Os mecanismos fisiopatológicos e as manifestações clínicas envolvidos têm sido mais bem reconhecidos e muitas de tais doenças são potencialmente tratáveis por imunossupressão ou imunomodulação com imunoglobulina intravenosa (IVIg). IVIg vem sendo utilizada em uma variedade de doenças neurológicas imunomediadas, sendo alvo de amplo uso em doenças dos sistemas nervosos central e periférico.

Objetivo

Oferecer uma visão global sobre os principais tópicos relacionados aos mecanismos de ação e aos diferentes usos terapêuticos da IVIg na prática neurológica, principalmente em doenças neuromusculares.

imunoglobulina; doenças neuromusculares; autoimunidade; miopatia inflamatória

Clinical diseases and intravenous immunoglobulin use
Hematologic diseases	Idiopathic thrombocytopenic purpura; autoimmune hemolytic anemia; hemolytic disease of the newborn with severe hyperbilirubinaemia; parvovirus B19-associated aplasia; immune neutropenia; thrombotic thrombocytopenic purpura; acquired von Willebrand disease; acquired factor VIII inhibitor; prophylaxis (for graft-versus-host disease and infectious) after bone marrow transplantation (in recipients older than 20 years of age) and for B-cell chronic lymphocytic leukaemia
Rheumatologic diseases	Kawasaki disease, systemic lupus erythematosus (hematological, central and peripheral nervous system, serositis and renal activities), fibromyalgia
Dermatologic diseases	Autoimmune bullous disease (bullous pemphigoid, pemphigus vulgaris and foliaceus, linear IgA disease), erythema multiforme, toxic epidermal necrolysis, chronic urticaria, pyoderma gangrenosum, scleromyxedema, atopic dermatitis
Gastroenterological diseases	Severe Clostridium difficile colitis, inflammatory bowel disease
Primary immunodeficiencies	Prophylaxis in hypogammaglobulinaemia; severe combined Immunodeficiency; X-linked agammaglobulinaemia, common variable immunodeficiency disorders, immunodeficiency with hyper-IgM syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia (Louis-Bar syndrome), DiGeorge syndrome, Good syndrome (thymoma with immunodeficiency), X-linked lymphoproliferative syndrome, hyper-IgE syndrome
Miscellaneous	Prophylaxis in children with chronic HIV infection; autoimmune uveitis; Birdshot retinochoroidopathy, streptococcal toxic schock syndrome, systemic vasculitis, severe drug-induced antibody deficiency

Properties	Gammagard	Gammar-P	Gamunex	Octagam	Flebogamma	Sandoglobulina Privigen	Kiovig
Laboratory	ARC/Baxter	Aventis	Bayer	Octapharma	Grifols	CSL Behring	Baxter
Form	Powder	Powder	Liquid	Liquid	Liquid	Liquid	Liquid
Concentration (%)	5-10	5	10	5	5-10	10	10
Osmolarity	125-636	309	258	310-380	327-342	320	309
IgA (µg/mL)	<2.4	<25	46	<0.4	<0.003	<0.025	<0.14
Stabilizer	Glucose (20-40 mg)	Sucrose (50 mg)	None	Maltose	Sorbitol 5%	Proline	Sucrose
Salt (mg/mL)	8.5-17	5	Trace	0	<3.2	<1	5
Time of infusion (hours)	1.2-5	5-6	2	4-6	3.1	1.2-5	5-6
pH	6.4-7.2	6.4-7.2	4-4.5	5.1-6	5.6	4.8	6.4-7.2

Table 3 Major groups of neurological diseases for which intravenous immunoglobulin has been studied in clinical trials, case reports and currently used in practice²2 Elovaara I, Apostolski S, Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893-908. http://dx.doi.org/10.1111/j.1468-1331.2008.02246.x
https://doi.org/10.1111/j.1468-1331.2008... ^,¹⁸18 Hughes RAC, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol. 2009;158(Suppl):34-42. http://dx.doi.org/10.1111/j.1365-2249.2009.04025.x
https://doi.org/10.1111/j.1365-2249.2009... ^,²¹21 Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367-75. http://dx.doi.org/10.1001/jama.291.19.2367
https://doi.org/10.1001/jama.291.19.2367... ^,²²22 Stangel M. New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord. 2008;1(2):52-61. http://dx.doi.org/10.1177/1756285608095747
https://doi.org/10.1177/1756285608095747... ^,²³23 Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3(1):36-44. http://dx.doi.org/10.1038/ncpneuro0376
https://doi.org/10.1038/ncpneuro0376... ^,²⁴24 Wiles C, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72(4):440-8. http://dx.doi.org/10.1136/jnnp.72.4.440
https://doi.org/10.1136/jnnp.72.4.440... ^,²⁵25 Cursiefen S, Mäurer M. Current use of immunoglobulins in neurology. Nervenarzt. 2008;79(2 Suppl):67-74. 10.1007/s00115-008-2461-y
https://doi.org/10.1007/s00115-008-2461-... ^,²⁶26 Winkelmann A, Zettl UK. Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system. Curr Pharm Des. 2012;18(29):4570-82. http://dx.doi.org/10.2174/138161212802502314
https://doi.org/10.2174/1381612128025023... .

Intravenous immunoglobulin and groups of neurological diseases
Neuromuscular Diseases	Inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis – sporadic and autosomal recessive hereditary type), neuromuscular junction disorders (myasthenia gravis class II/III Osserman-Genkins classification, myasthenic crisis or exacerbation), peripheral neuropathy and polyradiculoneuropathy (proximal subacute diabetic neuropathy, multifocal motor neuropathy, Guillain-Barré syndrome and variants, Chronic inflammatory demyelinating polyneuropathy, critical illness polyneuropathy and/or myopathy, autoimmune autonomic ganglionopathy), motor neuron disease (post-Polio syndrome), others (complex regional pain syndrome type 1, formerly known as reflex sympathetic dystrophy or Sudeck’s atrophy; resistant neuropathic pain)
Dementia and cognitive disorders	Alzheimer’s disease, Mild cognitive impairment
Cerebellar ataxias	Spinocerebellar ataxias, sporadic cerebellar ataxia (including the cerebellar predominant variant of multiple system atrophy)
Demyelinating diseases	Relapsing-remitting multiple sclerosis, acute disseminated encephalomyelitis, anti-aquaporin 4 antibody positive neuromyelitis optica spectrum disorder, optic neuritis, chronic relapsing inflammatory optic neuropathy (CRION)
Paraneoplastic neurological disorders	Limbic encephalitis (anti-VGKC, anti-Hu, anti-Ma2, anti-CV2/CRMP5), subacute sensory neuronopathy (anti-Hu, anti-CV2/CRMP5), opsoclonus-myoclonus (anti-Ri, anti-Hu, anti-Ma2, anti-amphiphysin), cerebellar paraneoplastic degeneration (anti-Yo, anti-Hu, anti-Tr, anti-CV2/CRMP5, anti-VGCC), Lambert-Eaton myastenic syndrome (anti-VGCC), peripheral nerve hyperexcitability in Isaacs’ syndrome (anti-VGKC)
Miscellaneous	HIV-associated vacuolar myelopathy, Japanese encephalitis, Rasmussen encephalitis, refractory autoimmune epilepsy with partial seizures, Stiff-person syndrome, PANDAS syndrome (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections), ischaemic stroke, Susac’s syndrome, narcolepsy

Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence: Wladimir Bocca Vieira de Rezende Pinto; Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo; Rua Pedro de Toledo, 650; 04023-900 São Paulo SP, Brasil; E-mail: wladimirbvrpinto@gmail.com